Diagnosis and management of primary aldosteronism: An updated review

Annals of Medicine

Volumn 45, Issue 4, 2013, Pages 375-383

  Chao, Chia Ter ^a,f   Wu, Vin Cent ^a,f   Kuo, Chin Chi ^a,f   Lin, Yen Hung ^b,f   Chang, Chin Chen ^c,f   Chueh, S Jeff ^d   Wu, Kwan Dun ^a,f   Pimenta, Eduardo ^e   Stowasser, Michael ^e  

^a Renal Division   (Taiwan)

^b Division of Cardiology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f TAIwan Primary Aldosteronism Investigators   (Taiwan)

Author keywords

Adenoma; Aldosteronism; Hyperplasia; Hypertension

Indexed keywords

ALDOSTERONE; ALISKIREN; CAPTOPRIL; CLONIDINE; DIGOXIN; DOXAZOSIN; EPLERENONE; FLUDROCORTISONE; LOSARTAN; METHYLDOPA; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; PRAZOSIN; RENIN; SALICYLIC ACID; SPIRONOLACTONE; TERAZOSIN;

ADRENALECTOMY; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOTOXICITY; CLINICAL DECISION MAKING; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DIZZINESS; DRUG DOSE TITRATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; EPITHELIUM CELL; ERECTILE DYSFUNCTION; FAMILIAL DISEASE; FATIGUE; GYNECOMASTIA; HALF LIFE TIME; HEADACHE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PALPITATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INCIDENCE; INFUSION; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; MUSCLE CRAMP; MUSCLE WEAKNESS; NEUTROPHIL; NOCTURIA; POLYDIPSIA; POLYURIA; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SALT INTAKE; SALT LOADING; SCREENING TEST; SHORT COURSE THERAPY; SIDE EFFECT; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOMA; ADRENAL CORTEX; ADRENAL HYPERPLASIA, CONGENITAL; ADRENALECTOMY; ALDOSTERONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION;

EID: 84878592782     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.785234     Document Type: Review

References (75)

1. Conn J. Presidential address. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955; 45: 6-17.
2. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93: 3266-81.
3. Hiramatsu K, Yamada T, Yukimura Y. A screening test to identify aldosterone- producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med. 1981; 141: 1589-93.
4. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2005; 20 : 129 -36.
5. Amar L, Plouin P-F, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010; 5:
6. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature. Horm Metab Res. 2012; 44: 157-62.
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006; 48: 2293-300.
8. Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007; 92 : 1863 -70.
9. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010; 31: 1237-47.
10. Rocha R, Funder JW.-pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002; 970: 89-100.
11. Lu ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-8.
12. Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, et al. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab. 2011; 96 : 3175 -83.
13. Kuo CC, Wu VC, Tsai CW, Wu KD. Relative kidney hyperfi ltration in primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2011; 12: 113-22.
14. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009; 94: 1191-7.
15. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007; 66: 607-18.
16. Lee P-H, Wu C-J, Chen Y-C, Chen H-H. Aldosterone-producing adenoma: clinical presentation, diagnosis and outcomes of surgery in Northern Taiwan. Acta Nephrol. 2009; 23: 143-8.
17. Omura M, Sasano H, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. Hypertens Res. 2006; 29: 883-9.
18. Kuo C-C, Wu V-C, Huang K-H, Wang S-M, Chang C-C, Lu C-C, et al. Verifi cation and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group). J Renin Angiotensin Aldosterone Syst. 2011; 12: 348-57.
19. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res. 2004; 27 : 303 -10.
20. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005; 111 : 871 -8.
21. Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiff ness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res. 2011; 34 : 286 -8.
22. Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2012; 26: 485-95.
23. Médeau V, Moreau F, Trinquart L, Clemessy M, W é meau J-L, Vantyghem MC, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol. 2008 ; 69 : 20 -8.
24. Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012; 44: 208-14.
25. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, et al. Aldosterone induces a vascular infl ammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002; 283 : H1802 -10.
26. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, et al. Arterial stiff ness, intima-media thickness and carotid artery fi brosis in patients with primary aldosteronism. J Hypertens. 2008; 26 : 2399 -405.
27. Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab. 2011; 96: E878-83.
28. Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006; 2: 198-208.
29. Rayner B. Primary aldosteronism and aldosterone-associated hypertension. J Clin Pathol. 2008; 61: 825-31.
30. S eccia T M, F assina A, N ussdorfer G G, P essina A C, R ossi G P. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn ' s syndrome with an ominous clinical course. Endocrine Relat Cancer. 2005; 12: 149-59.
31. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004; 12: 44-8.
32. Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics. Trend Endocrinol Metab. 2003; 14: 310-7.
33. So A, Duff y D L, G ordon R D, J eske Y W, L in-Su K, N ew M I, et a l. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005; 23 : 1477 -84.
34. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lift on RP. A novel form of human mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 2008; 93 : 3117 -23.
35. Mulatero P, Tauber P, Zennaro M-C, Monticone S, Lang K, Beuschlein F, et al. KCNJ5 Mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012; 59: 235-40.
36. Choi M, Scholl UI, Yue P, Bj ö rklund P, Zhao B, Nelson-Williams C, et al. K channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. Science. 2011; 331: 768-72.
37. McEwan PE, Lindop GB, Kenyon CJ. Control of cell proliferation in the rat adrenal gland in vivo by the renin-angiotensin system. Am J Physiol Endocrinol Metab. 1996; 271: E192-8.
38. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ' non-selective ' screening of hypertensive patients. J Hypertens. 2003; 21: 2149-57.
39. Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med. 1975; 5: 189-202.
40. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to defi ne aldosterone-to-renin ratio for primary aldosteronism. J Hypertens. 2004; 22: 377-81.
41. O livieri O, C iacciarelli A, S ignorelli D, P izzolo F, G uarini P, P avan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo Study. J Clin Endocrinol Metab. 2004; 89: 4221-6.
42. Abdelhamid S, Blomer R, Hommel G, Haack D, Lewicka S, Fiegel P, et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens. 2003; 16: 522-30.
43. Mourad J-J, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone- producing adenomas. Am J Hypertens. 2008; 21: 742-47.
44. Bernini G, Moretti A, Orlandini C, Berti P, Miccoli P, Bardini M, et al. Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens. 2008; 26: 981-8.
45. Yamashita K, Okuyama M, Nakagawa R, Honma S, Satoh F, Morimoto R, et al. Development of sensitive derivatization method for aldosterone in liquid chromatography -electrospray ionization tandem mass spectrometry of corticosteroids. J Chromatogr A. 2008; 1200: 114-21.
46. Chappell DL, McAvoy T, Weiss B, Weiner R, Laterza OF. Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC -MS/MS. Bioanalysis. 2012; 4 : 2843 -50.
47. Taylor PJ, Gordon RD, Stowasser M. Calibrators for measuring aldosterone by liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2012; 413: 346-7.
48. Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC -tandem mass spectrometry. Clin Chem. 2009; 55: 1155-62.
49. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Infl uence of antihypertensive medication on aldosterone and renin concentration in the diff erential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. 2002; 57: 457-65.
50. Grasko JM, Nguyen HH, Glendenning P. Delayed diagnosis of primary hyperaldosteronism. BMJ. 2010; 340: c2461.
51. Pizzolo F, Pavan C, Corrocher R, Olivieri O. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens. 2007; 20: 1334-7.
52. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from fi ve continents. J Clin Endocrinol Metab. 2004; 89 : 1045 -50.
53. Hannemann A, Friedrich N, L ü demann J, V ö lzke H, Rettig R, Peters J, et al. Reference intervals for aldosterone, renin, and the aldosterone-torenin ratio in the population-based Study of Health in Pomerania (SHIP-1). Horm Metab Res. 2010; 42: 392-9.
54. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001; 76: 877-82.
55. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confi rming primary aldosteronism. Hypertension. 2001; 37 : 1440 -3.
56. Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension. 2007; 50: e26-7.
57. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf). 1992; 36: 499-503.
58. Wu VC, Chueh SC, Chang HW, Lin WC, Liu KL, Li HY, et al. Bilateral aldosterone-producing adenomas: diff erentiation from bilateral adrenal hyperplasia. QJM. 2008; 101 : 13 -22.
59. Küpers EM, Amar L, Raynaud A, Plouin P-F, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012; 97: 3530-7.
60. Young Jr WF, Stanson AW, Th ompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004; 136: 1227-35.
61. D aunt N. A drenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005; 25: S143-58.
62. R ossi G P, S acchetto A, C hiesura-Corona M, D e Toni R, G allina M, Feltrin GP, et al. Identifi cation of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance fi ndings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001; 86: 1083-90.
63. Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009; 50: 1631-7.
64. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specifi city of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn ' s adenomas. J Clin Endocrinol Metab. 2012; 97: 100-9.
65. Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens. 2001; 15 : 173 -6.
66. Fu B, Zhang X, Wang G-X, Lang B, Ma X, Li H-Z, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2011; 185 : 1578 -82.
67. Lin Y-H, Lee H-H, Liu K-L, Lee J-K, Shih S-R, Chueh S-C, et al. Reversal of myocardial fi brosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery. 2011; 150: 526-33.
68. Wu V-C, Kuo C-C, Wang S-M, Liu K-L, Huang K-H, Lin Y-H, et al. Primary aldosteronism: changes in cystatin C-based kidney fi ltration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011; 29 : 1778 -86.
69. Sywak M, Pasieka JL. Long-term follow-up and cost benefi t of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002; 89 : 1587 -93.
70. Sawka AM, Young WF, Th ompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001; 135: 258 -61.
71. Kater CE, Biglieri EG, Schambelan M, Arteaga E. Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. Hypertension. 1983; 5: V115-21.
72. Jeunemaitre X, Chatellier G, Kreft -Jais C, Charru A, Devries C, Plouin P-F, et al. Effi cacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987; 60: 820-5.
73. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348 : 1309 -21.
74. Parthasarathy HK, M é nard J, White WB, Young WFJ, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011; 29 : 980 -90.
75. Farquharson CAJ, Struthers AD. Spironolactone Increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101 : 594 -7.